Arca
Skip to content
Tools
Tools

P: DNA polymerase/reverse transcriptase

Protein in Hepatitis B virus that 10 drugs act on.

  • Drugs that act on it: 10
  • Approved: 5
  • In phases 1 to 3: 5
  • Sponsors: 9

Who is on it, and how far along

Every drug ChEMBL records acting on P, by the furthest stage it has reached for any use, coloured by modality.

How to read this

Each mark is one drug. Columns run from approved to phase 1; hover or tap a mark for its sponsor, modality and open trials, and click it to open the drug.

  • Small molecule 10

Approved5

  • Tenofovir disoproxil
  • Lamivudine
  • Telbivudine
  • Adefovir dipivoxil
  • Entecavir anhydrous

Phase 33

  • Adefovir
  • Pradefovir
  • Tenofovir anhydrous

Phase 22

  • Elvucitabine
  • LB80380

Phase 10

    Sponsors

    Drugs on this target per company: the US application holder, else the industry sponsor leading the most of its trials.

    The landscape

    Every drug acting on it, furthest along first. The sponsor is the US application holder where there is one, else the industry lead sponsor of most of its registered trials. All act as: DNA polymerase/reverse transcriptase inhibitor.
    Tenofovir disoproxilBoxed warningApprovedGilead SciencesSmall moleculeInhibitor160
    LamivudineBoxed warningApprovedViiV HealthcareSmall moleculeInhibitor64
    TelbivudineBoxed warningApprovedNovartis PharmaceuticalsSmall moleculeInhibitor1
    Adefovir dipivoxilBoxed warningApprovedGilead SciencesSmall moleculeInhibitor0
    Entecavir anhydrousBoxed warningApprovedJohnson & JohnsonSmall moleculeInhibitor0
    AdefovirPhase 3Jiangsu Hansoh PharmaceuticalSmall moleculeInhibitor1
    PradefovirPhase 3Bausch HealthSmall moleculeInhibitor1
    Tenofovir anhydrousPhase 3Hepatera Ltd.Small moleculeInhibitor0
    ElvucitabinePhase 2AstraZeneca PharmaceuticalsSmall moleculeInhibitor0
    LB80380Phase 2LG Life SciencesSmall moleculeInhibitor0

    Open trials

    The most recently posted recruiting or ongoing trials naming each drug (up to 8 a drug), 18 in all, from ClinicalTrials.gov.
    Phase Ib Clinical Trial of ACT201 Injection in Participants With Treatment-Naïve Chronic Hepatitis BTenofovir disoproxilPhase 1Not yet recruitingXiamen Amoytop Biotech Co., Ltd.Nov 18, 2026
    People With Active Viremia Treated With Lenacapavir and Long-Acting Cabotegravir for EffectivenessTenofovir disoproxilPhase 1Not yet recruitingNational Institute of Allergy and Infectious Diseases (NIAID)Nov 16, 2026
    Cohort of Women Living With HIV-1 and Receiving Bictegravir/Emtricitabine/Tenofovir AlafenamideTenofovir disoproxil—RecruitingCentre de Recherches et d'Etude sur la Pathologie Tropicale et le SidaNov 6, 2026
    Study of BIC/LEN FDC Versus Stable Baseline Regimens in Virologically Suppressed People With HIVTenofovir disoproxilPhase 4Not yet recruitingGilead SciencesNov 2, 2026
    Starting HIV Prevention Medicine (PrEP) During an Emergency Department Visit With a Peer NavigatorTenofovir disoproxilPhase 4Not yet recruitingUniversity of South FloridaOct 28, 2026
    Effects of Switch to Doravirine/Islatravir vs. Continued Antiretroviral Therapy on Biomarkers of Aging Among Virologically Suppressed People With HIVLamivudine, Tenofovir disoproxilPhase 2Not yet recruitingThe University of Texas Health Science Center, HoustonOct 13, 2026
    Study on Retention in Care and on Clinical Chracteristics of HIV-infected Women Treated With Bictegravir/Emtricitabine/Tenofovir Alafenamide (BIKWO).Tenofovir disoproxil—Not yet recruitingEnte Ospedaliero Ospedali GallieraOct 6, 2026
    Substudy-01: A Study of Long-Acting HIV-1 Treatments Taken by Mouth in People With HIV-1 With Undetectable Virus LevelsTenofovir disoproxilPhase 2RecruitingGilead SciencesSep 25, 2026
    A Phase 2b Study Evaluating VH4011499 Capsid Inhibitor Long-Acting Injectable Plus Cabotegravir in Treatment Naïve Adults (CINERGY)LamivudinePhase 2Not yet recruitingViiV HealthcareSep 11, 2026
    An Adaptive Platform Trial for Evaluation of Novel Treatment Regimens in Children and Adolescents With HIV in AfricaLamivudinePhase 3Not yet recruitingUniversity College, LondonAug 28, 2026
    Effectiveness and Safety of Darunavir/Cobicistat Plus Lamivudine Compared With Darunavir/Cobicistat Plus Tenofovir Alafenamide/Emtricitabine in Virologically Suppressed People Living With HIV at 24 and 48 Weeks of Follow-upLamivudinePhase 4RecruitingInstituto Mexicano del Seguro SocialJul 1, 2026
    Sleep Outcomes and Multidimensional Sleep Assessment - a Randomized Trial of Dolutegravir- vs Doravirine-based Antiretroviral Therapy in People Living With HIVLamivudinePhase 4Not yet recruitingUniversity of Witwatersrand, South AfricaJun 29, 2026
    Lamivudine as a Novel Clinical Effort for Rett SyndromeLamivudinePhase 2Enrolling by invitationMaria Denise Fernandes Carvalho de AndradeJun 10, 2026
    Comparative Trial Between Ainuovirine(ANV)/Lamivudine(3TC)/Tenofovir(TDF) and Efavirenz(EFV)/Lamivudine/Tenofovir RegimensLamivudinePhase 4Not yet recruitingShanghai Public Health Clinical CenterJun 8, 2026
    Dolutegravir/Lamivudine in Treatment-Naïve Pregnant WomenLamivudinePhase 4RecruitingFundación HuéspedJun 1, 2026
    A Real-World Study on the Efficacy and Safety of Pradefovir Mesylate Tablets in the Treatment of Chronic Hepatitis BPradefovir—Active, not recruitingJuan LiApr 29, 2026
    Entecavir Resistance-Associated Mutations in Chronic HBV Patients in Turkey (STREAM Study)Telbivudine—RecruitingYaşar Bayındır, MDMar 9, 2026
    Halting Nucleoside Analogues in Chronic Hepatitis BAdefovirNot applicableActive, not recruitingSeng Gee LimSep 25, 2019

    Drugs, mechanisms, furthest stage (max phase) and modality (molecule type) are from ChEMBL CHEMBL2362994, ChEMBL 37, fetched 2026-11-18 (CC BY-SA 3.0). Sponsors are the US application holder (Drugs@FDA) for approved drugs with a US page, else the industry lead sponsor of the most of the drug's ClinicalTrials.gov trials. Open trials are recruiting or ongoing studies naming the drug as an intervention on ClinicalTrials.gov, checked daily; this page as of 2026-11-21. ChEMBL and Open Targets

    Esc

    Type a name: a tool, a company, a drug or brand, a condition, a gene or a state. Identifiers like K231234, NCT05012345 or NDA 215866 open their record.

    Logos are each company's own site icon, matched by name through Wikidata, or logos provided by Logo.dev.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.